Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.32 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1002353 | 1.00 | HDAC3 (0.32) | HDAC3HDAC1HDAC2HDAC6CACNA1G | |
| SCHEMBL1002351 | 1.00 | HDAC3 (0.32) | HDAC3HDAC1HDAC2HDAC6CACNA1G | |
| SCHEMBL1001980 | 0.86 | HDAC3 (0.34) | HDAC3HDAC1HDAC2HDAC6CACNA1G | |
| SCHEMBL1001979 | 0.86 | HDAC3 (0.34) | HDAC3HDAC1HDAC2HDAC6CACNA1G | |
| SCHEMBL1003335 | 0.84 | — | — | |
| SCHEMBL1003336 | 0.84 | — | — | |
| SCHEMBL1003337 | 0.84 | — | — | |
| SCHEMBL1001773 | 0.82 | HDAC3 (0.34) | HDAC3HDAC1HDAC2HDAC6CACNA1G | |
| SCHEMBL1001772 | 0.82 | HDAC3 (0.34) | HDAC3HDAC1HDAC2HDAC6CACNA1G | |
| SCHEMBL1003002 | 0.76 | S1PR3 (0.31) | TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015198-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM | BANYU PHARMACEUTICAL CO., INC. | 2011-01-20 | — | — | US | disclosed |
| EP-2272841-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING ANTAGONISTIC ACTIVITY ON MELANIN-CONCENTRATING HORMONE RECEPTOR | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015198-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM | MC1R, MCHR2, MCHR1 | HDAC3 1547/4885HDAC1 2185/4885HDAC2 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.